OTCMKTS:APLIF Appili Therapeutics (APLIF) Stock Price, News & Analysis $0.03 0.00 (0.00%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort Interest About Appili Therapeutics Stock (OTCMKTS:APLIF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Appili Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.05Volume895 shsAverage Volume162,202 shsMarket Capitalization$3.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Appili Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks15th Percentile Overall ScoreAPLIF MarketRank™: Appili Therapeutics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Appili Therapeutics.Read more about Appili Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Appili Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Appili Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Appili Therapeutics have been sold short.Short Interest Ratio / Days to CoverAppili Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Appili Therapeutics has recently decreased by 99.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAppili Therapeutics does not currently pay a dividend.Dividend GrowthAppili Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Appili Therapeutics have been sold short.Short Interest Ratio / Days to CoverAppili Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Appili Therapeutics has recently decreased by 99.04%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.50 News SentimentAppili Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Appili Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Appili Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Appili Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Appili Therapeutics' insider trading history. Receive APLIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLIF Stock News HeadlinesAppili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA SubmissionOctober 31 at 7:15 AM | globenewswire.comCritical Analysis: Appili Therapeutics (OTCMKTS:APLIF) & BioCardia (NASDAQ:BCDA)October 25, 2024 | americanbankingnews.comI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. October 31, 2024 | Porter & Company (Ad)Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024October 17, 2024 | globenewswire.comAppili Therapeutics – Press Release CorrectionOctober 10, 2024 | globenewswire.comAppili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of ShareholdersOctober 10, 2024 | globenewswire.comAditxt Delivers Shareholder Update and 2024 Year-End PlanOctober 3, 2024 | finance.yahoo.comAppili Therapeutics Inc (APLI)October 2, 2024 | investing.comSee More Headlines APLIF Stock Analysis - Frequently Asked Questions How have APLIF shares performed this year? Appili Therapeutics' stock was trading at $0.0265 on January 1st, 2024. Since then, APLIF stock has increased by 4.2% and is now trading at $0.0276. View the best growth stocks for 2024 here. How were Appili Therapeutics' earnings last quarter? Appili Therapeutics Inc. (OTCMKTS:APLIF) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). How do I buy shares of Appili Therapeutics? Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/13/2024Today10/31/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:APLIF CUSIPN/A CIKN/A Webwww.appilitherapeutics.com Phone902-442-4655FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,800,000.00 Net Margins-450.64% Pretax MarginN/A Return on EquityN/A Return on Assets-186.27% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual Sales$630,000.00 Price / Sales5.31 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-0.55Miscellaneous Outstanding Shares121,266,000Free Float106,908,000Market Cap$3.35 million OptionableNot Optionable Beta-0.48 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (OTCMKTS:APLIF) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Appili Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.